Low-grade glioma, pancreatic cancer BRAF fusion gene, BRAF rearrangement, low-grade glioma, pancreatic cancer
Conditions
Interventions
Binimetinib is administered 45 mg orally, twice daily.
C000581313
Binimetinib MEK inhibitor
Sponsors
Morizane Chigusa
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria for both cohort A and B 1) BRAF fusion or rearrangement is detected by reimbursed NGS-based cancer gene panel tests, cancer gene panel tests performed under advanced medical treatment, or clinical study (including liquid biopsy). Patients who have a result of BRAF fusion or rearrangement from cancer gene panel tests other than OncoGuide NCC Oncopanel System have to give consent and be able to submit tissue specimen (Unstained slides of 10 micrometer x 5 slides (5 micrometer x 10 slides) with percent tumor nuclei content of 20 percent or more) which is necessary for the development and application for companion diagnostics. 2) Unresectable or recurrent 3) No symptomatic brain metastasis, carcinomatous meningitis or spinal metastasis requiring surgical intervention or radiotherapy 4) No cardiac effusion, pleural effusion, or ascites requiring treatment 5) Not received anti-cancer drug within 14 days before registration, nor received other study drug (molecular targeting drug, immune therapy) within 21 days before registration 6) Not received operation under general anesthesia within 28 days before registration 7) Not received radiation therapy (including gamma knife, cyber knife) within 14 days before registration 8) Left ventricular ejection fraction is 50 percent or over by echocardiography or MUGA (multigated acquisition scan) within 28 days before registration 9) Having all laboratory tests performed within 14 days before registration and the values are within the following range. Patients should not receive administration of G-CSF and/or blood transfusion within 14 days before the blood collection (1) Absolute neutrophil count >= 1.500/mm3 (2) Platelet count >= 10.0 x 10000/mm3 (3) Hemoglobin >= 8.0 g/dL (4) Total bilirubin = 70 for patients 12-15 years old Karnofsky Performance Status (KPS) >= 70 for patients 16 years or older 16) Having measurable disease within 28 days before registration 17) Patients suffice the following. (1) Having adequate initial treatment depending on the primary central nervous tumor including surgery if recommended treatment is available. (2) Neurologically stable. (3) Multiple lesion or dissemination is not detected with MRI at the registration. 18) Not increased steroid for low-grade glioma
Exclusion criteria
Exclusion criteria: 1) Active double primary cancer (but not (1)-(3)): (1) completely resected following cancers: basal cell carcinoma, stage I squamous cell carcinoma, carcinoma in situ, intramucosal carcinoma, superficial bladder cancer, (2) gastrointestinal cancer curatively resected with ESD or EMR, and (3) other cancers with no recurrence for more than 5 years. 2) Patients with symptomatic congestive heart failure of NYHA class II-IV or arrythmia (over grade 2) occurring in less than 6 months before registration. 3) Patients with myocardial infarction or unstable angina occurring in less than 6 months before registration. 4) Patients with corrected QT interval (QTcF) >480 ms in ECG performed within 14 days before enrollment. 5) Patients with infections requiring systemic treatment. 6) Patients with uncontrolled hypertension (systolic blood pressure: over 150 mmHg or diastolic blood pressure: over 100 mmHg). 7) Patients with history or findings of retinal vein occlusion (RVO) or having RVO risk factor (unstable glaucoma, ocular hypertension, hyperviscosity syndrome, hypercoagulability syndrome, etc.) 8) Patients with history or complication of retinal degenerative disease other than RVO (central serous chorioretinopathy, retinal detachment, age-related macular degeneration, etc.) 9) Patients with uncontrolled diabetes mellitis. 10) Patients with venous thrombus (transient ischemic attack, stroke, massive deep vein thrombosis, pulmonary embolism, etc.) occurring in less than 3 months 11) Patients who have neuromuscular disease with CK elevation (inflammatory myopathy, muscular dystrophy, amyotrophic lateral sclerosis, spinal muscular atrophy, etc.). 12) Prior treatment with MEK inhibitors. 13) Previous severe hypersensitive reaction to ingredient including binimetinib. 14) Patients who are positive for either HIV antibody, HBs antigen, or HCV-RNA. 15) Negative for HBs antigen, positive for HBs antibody or HBc antibody, and positive for HBV-DNA assay. (If it is less than or equal to the detection sensitivity, patients are not excluded) 16) Patients with concomitant diseases that affect gastrointestina function. 17) Women who are pregnant, breastfeeding and need to continue breastfeeding in the future, and women who may be pregnant. 18) Patients with psychiatric diseases or psychological symptoms interfering with participation in the trial. 19) Patients who are deemed inappropriate for participation in the trial by the principal investigator or sub-investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate (centrally assessed) | — |
Secondary
| Measure | Time frame |
|---|---|
| Cohort A Response rate(investigator assessed by RECIST), response rate(investigator assessed by RANO), response rate including minor response(investigator assessed by RANO), progression-free survival, overall survival, disease control rate, duration of response, and incidence of adverse events Cohort B Response rate(investigator assessed by RECIST), progression-free survival, overall survival, disease control rate, duration of response, and incidence of adverse events | — |
Contacts
Public ContactNCCH2101 Clinical trial Coordinating office
National Cancer Center Hospital
Outcome results
None listed